respiratory
Medicines

PAH drug under safety review


The European medicines safety agency is reviewing the safety of the PAH drug selexipag (Uptravi) following the deaths of 5 patients taking the medicine in France. However, an advisory note published on its website the European Medicines Agency (EMA) says that based on a preliminary review of the available data Uptravi may continue to be ...

Already a member?

Enter your email to keep reading.


OR